Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach

Br J Haematol. 2016 Aug;174(3):473-7. doi: 10.1111/bjh.13776. Epub 2015 Oct 12.

Evren Alici^{1

2

3}, Michael Chrobok^{1

3}, Johan Lund^{1

2}, Tahamtan Ahmadi⁴, Imran Khan⁴, Adil D Duru^{1

3}, Hareth Nahi^{5

6

7}

¹ Centre for Haematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
² Haematology Centre, Karolinska University Hospital Huddinge, Stockholm, Sweden.
³ Center for Diseases of Aging, Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL, USA.
⁴ Janssen Research & Development LLC, Spring House, PA, USA.
⁵ Centre for Haematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. [email protected].
⁶ Haematology Centre, Karolinska University Hospital Huddinge, Stockholm, Sweden. [email protected].
⁷ Center for Diseases of Aging, Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL, USA. [email protected].

No abstract available

Keywords: CD38; daratumumab; relapsed and refractory multiple myeloma; response.

Publication types